BPIQ Pro/Elite/Apex Investor Posts

APLS

Our Top 50 StR portfolio targets have been substantially updated. See new targets at the link below.

Another interesting company to diligence is Dyne Therapeutics (DYN) . Their shares were hit pretty hard this week, apparently because they changed primary outcomes for their upcoming DMD readout. Did the market over-react to that, and in the wrong direction? That is something to dig deeper into.

An interesting company to diligence is ACRS (Aclaris) - they have 2 Big Mover readouts coming this month for 2 different assets, and their market cap is less than $200M, yet 7 hedge funds hold them. It's very rare for this many hedge funds to hold a company with that market cap. However, in 2021 their market cap was 10X current, and we find that biopharma-focused hedge funds are not in a rush to pull out of holdings where they have lost big. We have not traced the hedge fund

It was good to see SCPH up ~25% on their quarterly update in May. Company still only ~$200M market cap, so plenty of room to run up this year.

Updated targets for the Top 10 , Top 15 , and Top 20  BPIQ Elite model portfolios are now available. 👇

Summary

FYI - We updated our targets for our Run-Up fund and started making trades towards the new targets today.

As we have discussed in prior posts , we transitioned our BPIQ model portfolios to strategies that utilized top holdings of bio/pharma-focused funds. This post updates the performance of those model portfolios in their first full year. Furthermore, this post presents results of more back-testing we performed as we tested similar and further refined sub-strategies based on hedge-fund favorite holdings. Four conclusions can be drawn from this work:

Summary

We updated our Top 10, Top 15, and Top 20 biopharma-focused Hedge fund favorite portfolios targets earlier this week. The updates are based on Q4 holdings of top biopharma hedge funds. The Top 20 hedge fund portfolio strategy uses a different methodology for identifying top holdings than the Top 10 portfolio and Top 15 portfolio. We plan to make trades in the coming week to align the holdings of these portfolios with the updated targets.

2024 was a remarkable year for cell and gene therapies (CGT) with the FDA approving nine innovative products. Read more below about these approved CGT therapies and new indications.

The following table provides info on the companies discussed in this article, including EV, short interest, current top biopharma-hedge fund holdings, and BPIQ portfolio holding percentages.

The 43rd Annual J.P. Morgan Health Care Conference  is taking place in San Francisco, CA from January 13-16, 2025 .

We’re always excited to find bio/pharma companies nearing their therapeutic product launch!

This post provides some ideas on how to Use BPIQ's Hedge Fund Data And Model Portfolios to Beat the Major Biotech ETFs.

TAKE HOME MESSAGE:

You can find updated Q3 bioHF holdings data at app.bpiq.com/hedgefunds

This weekend COGT reports some Big-Mover data on  Bezuclastinib (CGT9486) at ASH.

SUMMARY